S268: safety, tolerability, and pharmacokinetic/pharmacodynamic results from phase 1 studies of GBT021601, a next-generation HbS polymerization inhibitor for …

HemaSphere, 2022 - journals.lww.com
Background: Sickle cell disease (SCD) is caused by polymerization of sickle hemoglobin
(HbS). Voxelotor is a first-in-class HbS polymerization inhibitor approved by the United …
被引用次数：2 相关文章

[引用][C] S268: SAFETY, TOLERABILITY, AND PHARMACOKINETIC/PHARMACODYNAMIC RESULTS FROM PHASE 1 STUDIES OF GBT021601, A NEXT …

C Brown, C Key, I Agodoa, J Olbertz, K Duchin… - …, 2022 - Wiley Online Library
Background: Sickle cell disease (SCD) is caused by polymerization of sickle hemoglobin
(HbS). Voxelotor is a first-in-class HbS polymerization inhibitor approved by the United …